Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

* All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE)

* Current cash balance provides runway to the potential launch of IMVT-1402 in GD